Kairos Pharma (KAPA) Q1 2025 Annual Earnings
KAPA·Reported April 15, 2025·Before market open
Diluted EPS came in at $-0.08, missed the $-0.05 consensus by $0.03.
Diluted EPS
$-0.08missed by $0.03
Consensus: $-0.05
Financial Snapshot
Trailing eight quarters through Q1 2025
Q1 2025 Earnings FAQ
Common questions about Kairos Pharma's Q1 2025 earnings report.
Kairos Pharma (KAPA) reported Q1 2025 earnings on April 15, 2025 before market open.
Kairos Pharma reported diluted EPS of $-0.08 for Q1 2025.
EPS missed the consensus estimate of $-0.05 by $0.03.
You can read the 10-K periodic report (0001641172-25-004920) directly on SEC EDGAR. The filing index links above go to sec.gov.